On June 8, 2020, Ruxin (Beijing) Medical Systems Co., Ltd. was able to live up to the anxious waiting of relevant parties in Italy. Eight boxes of CE certified In-Line Exsufflators which model is CoughSync 100EU passed strict factory inspection, were delivered to UPS international express and sent to the customs for examination.

Currently, COVID-19 is raging around the world, and the trend of increasing infections has not been fully controlled. Clearing out large amounts of airway secretions is already an ordeal for mild patients, while for severe COVID-19 patients on invasive ventilators, only prompt sputum aspiration by ICU staff can save patients from the risk of suffocation. Prior to this, manual suction tube negative pressure sputum aspiration was the gold standard of ICU airway care worldwide and was almost the only option. In view of the current epidemic situation in Europe, the defects of the traditional manual sputum aspiration method have been multiplied, such as the risk of asphyxia caused by the inability to remove the sputum blocked in the bronchial tube, the risk of infection caused by direct contact with the patient's secretions, secondary trauma to the patient, and a amount of time that the medical staff in the ICU takes up, etc. 

The IL-MIE (In Line Mechanical Insufflation- Exsufflation), independently developed by Ruxin (Beijing) Medical Systems Co., Ltd., can minimize the risk of asphyxia due to obstructed secretions. In addition, the CoughSync 100EU not only automatically monitors and operates, but also avoids direct contact with airway secretions by ICU staff, greatly reducing the risk of infection for health care workers.

In the harsh global environment of COVID-19, Ruxin (Beijing) Medical Systems Co., Ltd. will do its best to provide the most advanced and applicable airway care products for the ICU invasive mechanical ventilation treatment, and will strive to "become a respected, internationally leading innovation-driven provider of medical devices and services."